FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
FOLFIRI联合贝伐单抗作为一线治疗后转移性结直肠癌患者的二线治疗:一项随机III期EAGLE研究
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdv197
Iwamoto, S; Takahashi, T; Tamagawa, H; Nakamura, M; Munemoto, Y; Kato, T; Hata, T; Denda, T; Morita, Y; Inukai, M; Kunieda, K; Nagata, N; Kurachi, K; Ina, K; Ooshiro, M; Shimoyama, T; Baba, H; Oba, K; Sakamoto, J; Mishima, H